Health

RIVM starts research into the long-term effectiveness of COVID-19 vaccines

VASCO

‘The Corona Vaccination Study (VASCO) aims to provide insight in all age groups into the extent to which the various vaccines offer protection and how long this protection lasts,’ says the RIVM. It is also being investigated whether and to what extent the vaccines offer protection against new variants of SARS severe acute respiratory syndrome -CoV coronavirus -2. Anyone who lives in the Netherlands and is between 18 and 85 years old can participate in the study.

Never before

Never before has the entire population (aged 18 years and older) been invited in a short period of time to receive newly developed vaccines against a new virus. With VASCO, 50,000 Dutch people will be followed for 5 years. This research will monitor the (long-term) effectiveness of the vaccines in practice and will be able to compare the different vaccines. Both in the general population and in risk groups. VASCO is carried out by the RIVM National Institute for Public Health and the Environment, in collaboration with Julius Clinical and the UMC University Medical Center Utrecht.

Research into effectiveness in practice

The COVID-19 vaccines have been tested for effectiveness and safety prior to registration. Because both the virus and the vaccines are new, the duration of protection is still unknown. In pre-registration studies, limited research is conducted into the effect of the vaccines in risk groups, such as the elderly or people with underlying diseases. Studies to monitor the (long-term) effectiveness of the vaccines in practice and to be able to compare the different vaccines are therefore necessary. Both in healthy persons and in persons belonging to risk groups.

Research design

All residents in the Netherlands aged 18 to 85 can participate in the study. Both people who may or may not be vaccinated can participate. Participants will be followed for 5 years. At the time of participation, data is collected by means of a questionnaire via an app or website and a blood test by means of a finger prick that one can do yourself. This is necessary in order to take into account differences between people who have been vaccinated and who have not (yet) been vaccinated and to determine whether a participant has previously had a corona infection. This research is part of the evaluation of the national vaccination campaign and can contribute to the future fight against the corona virus.

Participation in the study

People can register for participation via www.rivm.nl/vasco. In addition, in the coming weeks, RIVM will be sending an invitation by letter to a large number of randomly selected people in the Netherlands to participate in the study.

RIVM starts research into the long-term effectiveness of COVID-19 vaccines
Source link RIVM starts research into the long-term effectiveness of COVID-19 vaccines

Back to top button